Login to Your Account

Ribo expanding RNA work in China with Ionis antisense deal

By Haky Moon
Staff Writer

Wednesday, April 26, 2017

HONG KONG – A deal inked between Calif.-based Ionis Pharmaceuticals Inc. and Kunshan, China-based Suzhou Ribo Life Science Co. Ltd. will ease the U.S. company's entry into the Chinese innovative drug market.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription